Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase II

Shortwave Life SciencesAQSE: PSY

1 Drug Candidate

Shortwave Life Sciences is a UK-listed biopharmaceutical company developing a proprietary psilocybin and beta-carboline buccal film formulation for the treatment of anorexia nervosa. The mucoadhesive film delivery system enables improved bioavailability and rapid onset by bypassing first-pass metabolism, and the company has secured an investigator-initiated Phase 2 clinical trial agreement with Sheba Medical Center in Israel — targeting a condition with no FDA-approved pharmacological treatment.

Drug Pipeline

1

Psilocybin + Beta-Carboline Buccal Film

Psilocybin
Phase II
Eating Disorders

Investigator-initiated Phase 2 open-label trial at Sheba Medical Center, Israel. Mucoadhesive buccal film with psilocybin and beta-carboline for anorexia nervosa patients.

Quick Facts

Type
Public Biotech
Ticker
AQSE: PSY
Lead Stage
Phase II
Website
Visit